- A potential antimalarial was trialled in animals as a single dose
- They found that it could block all life cycle stages of mosquitoes
- An expert says the drug could advance malaria control if it reaches the market
[CAPE TOWN] A new antimalarial candidate could pave the way for a single-dose treatment that boots malaria eradication when used in combination with other preventative measures.
In an article published last month (26 April) in the journal of Science Translational Medicine, researchers indicated that the compound MMV390048 could block all life cycle stages of the malaria parasite. It was also shown to be effective against resistant strains, prevent infection and block transmission.
“This drug profile reveals the potential to be part of a single-dose cure, benefitting people who are infected with malaria, and working as a preventative measure,” says Kelly Chibale, a corresponding author of the article and founding director of the University of Cape Town (UCT) Drug Discovery and Development Centre, H3D.